Analysts believe that Gilead's new PrEP drug Yeztugo could reach peak sales of $4.5 billion. Not if GSK has anything to say about it.

The FDA has approved a breakthrough preventative treatment for HIV that could change the course of the AIDS epidemic. But ...

Japan’s lack of generic PrEP options has made therapies inaccessible to most patients. Access to newer HIV therapies remains a major challenge in the global HIV treatment landscape, largely due to ...

This discovery could make treatment for an eye disease affecting millions with diabetes more accessible and affordable.

A federal judge has ruled that recent mass layoffs at the U.S. Department of Health and Human Services were likely unlawful ...

LOS ANGELES — HIV infections in LA County have been steadily declining for years, from nearly 7,000 per year in the 1990s to 1,400 in 2024, according to the Los Angeles County Department of Public ...

Is the cost of research aimed at curing HIV worth it, when HIV can be effectively managed and prevented by existing drugs?

Utah biochemist Wesley Sundquist has achieved yet another milestone with the Food and Drug Administration approval of an ...

Big Pharma delivers another life-saving medical advance, and another demonstration of the folly of price controls.

The FDA has approved Yeztugo (lenacapvir), a twice-yearly injection to prevent HIV infection that could improve adherence ...

Yeztugo, approved by the FDA, was highly effective in two randomized trials. It costs $28,218 per year, and people have to be ...

The new HIV PrEP option could drastically reduce the number of new cases by offering a new alternative to daily pills or ...